Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 21Lymphoma, Mantle-Cell 15Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Lymphoma, B-Cell 3Leukemia, B-Cell 3Waldenstrom Macroglobulinemia 2Lymphatic Diseases 2Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Glioblastoma 1Burkitt Lymphoma 1Anemia, Hemolytic, Autoimmune 1

Interventions

Cyclophosphamide 5ibrutinib 4fludarabine 4pirtobrutinib 3obinutuzumab 3acalabrutinib 3fludarabine phosphate 2Rituximab 2Mesna 2venetoclax 1ricolinostat 1idelalisib 1Whole-Body Irradiation 1Vincristine 1Tacrolimus 1Stem Cell Transplantation 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Melphalan 1Leukapheresis 1Doxorubicin 1Diet 1Busulfan 1Bone Marrow Transplantation 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, B-Cell × acalabrutinib × 90 days × Clear all
NCT05557695 2026-06-02

EPIC

AstraZeneca

Recruiting
350 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06564038 2026-05-14

Soundtrack-E

AstraZeneca

Phase 1/2 Recruiting
408 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡